Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of NASDAQ EVOK opened at $4.82 on Monday. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $12.32. The stock has a market cap of $7.18 million, a PE ratio of -0.44 and a beta of 0.16. The stock has a fifty day moving average of $4.71 and a 200-day moving average of $4.82.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.